---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-013277"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:56:15.227465+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# BioLife Solutions issues routine investor presentation; no material news disclosed

## Summary
- Investor presentation released on March 2, 2026, highlights cell-based therapy solutions.
- Presentation available at company's investor relations website.
- No financial results, guidance changes, or strategic initiatives included in the filing.

## SEC filing metadata
- accession: 0001628280-26-013277
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/0001628280-26-013277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/blfs-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-013277
- JSON: https://secwatch.observer/filing/0001628280-26-013277.json
- Plain text: https://secwatch.observer/filing/0001628280-26-013277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.